The 10-Item Sickle Cell Disease Severity Measure (SCDSM-10): A Novel Measure of Daily SCD Symptom Severity Developed to Assess Benefit of GBT440, an Experimental HbS Polymerization Inhibitor

被引：2

|

作者：

Burke, Laurie ^{[1
]}

Hobart, Jeremy Charles ^{[2
]}

Fox, Kathleen ^{[3
]}

Lehrer-Graiwer, Josh ^{[4
]}

Bridges, Kenneth ^{[4
]}

Kraus, Martine ^{[4
]}

Ramos, Eleanor ^{[4
]}

机构：

[1] Lora Grp, Royal Oak, MD USA

[2] Peninsula Coll Med & Dent, Plymouth, Devon, England

[3] Healthvibe, LLC, Baltimore, MD USA

[4] Global Blood Therapeut, South San Francisco, CA USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.4760.4760

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4760

引用

收藏

页数：4

相关论文

共 3 条

[1] Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor
Lehrer-Graiwer, Josh
Howard, Jo
Hemmaway, Claire Jane
Awogbade, Moji
Telfer, Paul
Layton, Mark
Porter, John B.
Mant, Timothy
Dufu, Kobina
Hutchaleelaha, Athiwat
Oksenberg, Donna
Patel, Mira
Tonda, Margaret Eleanor
Bridges, Kenneth
Ramos, Eleanor
BLOOD, 2016, 128 (22)
[2] Absorption, Metabolism and Excretion of GBT440, a Novel Hemoglobin S ( HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease ( SCD), in Healthy Male Subjects
Rademacher, Peter
Hutchaleelaha, Athiwat
Washington, Carla
Lehrer, Josh
Ramos, Eleanor
BLOOD, 2016, 128 (22)
[3] PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF GBT440, A NOVEL HEMOGLOBIN S (HBS) POLYMERIZATION INHIBITOR FOR THE TREATMENT OF SICKLE CELL DISEASE (SCD), IN HEALTHY VOLUNTEERS AND SCD PATIENTS
Patel, M.
Hutchaleelaha, A.
Siu, V.
Silva-Garcia, A.
Oksenberg, D.
Lehrer-Graiwer, J.
Mant, T.
Ramos, E.
HAEMATOLOGICA, 2016, 101 : 124 - 125